Guangdong Zhongsheng Pharmaceutical Co., Ltd. and all members of the board guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
Recently, according to the public information released by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, the innovative drug Anladiwei Granules, developed by Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (hereinafter referred to as "Zhongsheng Ruichuang"), a subsidiary of Guangdong Zhongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company"), has been included in the priority review list by the CDE. The CDE prioritizes the allocation of resources for the review of drug marketing authorization applications included in the priority review process based on the order of acceptance of registration applications. The specific details are as follows: